Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Expanded Access
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Category: Publications
Home
Publications
20
Apr
2019
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
0
0
April 20, 2019
April 20, 2019
20
Apr
2019
ABI-009 (
nab
-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
0
0
April 20, 2019
April 20, 2019
31
Mar
2019
Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009,
nab
-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
0
0
March 31, 2019
March 31, 2019
31
Jan
2019
A phase I/II multicenter study of ABI-009 (
nab
-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
0
0
January 31, 2019
January 31, 2019
31
Dec
2018
Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (
nab
-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
0
0
December 31, 2018
December 31, 2018
20
Jun
2018
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (
nab
-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)
0
0
June 20, 2018
June 20, 2018
20
Apr
2018
Antitumor activity of ABI-009 (
nab
-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
0
0
April 20, 2018
April 20, 2018
Previous
1
2
3
4
5
6
Next